Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell engager.
Location: United States
Total raised: $62M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.06.2026 | Series B | $62M | Pfizer Ven... |
Mentions in press and media 4
| Date | Title | Description |
| 02.07.2026 | Oblenio Bio Secures $62M to Advance Autoimmune Immune Reset Therapy LBL-051 into Clinic | Oblenio Bio raised $62 million in Series B funding. Pfizer Ventures led the round, with Deep Track Capital and GV joining. Funds will advance LBL-051, a tri-specific T-cell engager, into clinical development. LBL-051 targets refractory auto... |
| 27.06.2026 | Oblenio Bio Raises $62 Million Series B To Advance Autoimmune Disease Therapy | Oblenio Bio announced that it has closed an oversubscribed $62 million Series B financing round to advance its lead autoimmune disease program into clinical development. The round was led by Pfizer Ventures, with participation from new inve... |
| 25.06.2026 | Oblenio Bio Closes $62M Series B Funding | Oblenio Bio, a Cambridge, MA-based company which specializes in the treatment of autoimmune diseases, raised $62M in Series B funding. The round was led by Pfizer Ventures, with participation from new investors Deep Track Capital and GV, al... |
| - | Oblenio Bio | “Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell engager.” |